Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02705105 · ClinicalTrials.gov registry record · Phase 1
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Cancer and Solid Tumor, sponsored by Kyowa Kirin.
- Completed
- Registry status
- Phase 1
- Development phase
- 114
- Enrollment target
- 15
- Study locations
NCT02705105: Completed Phase 1 study of Cancer and Solid Tumor, sponsored by Kyowa Kirin.
NCT02705105 is a Phase 1 study of Cancer and Solid Tumor that has completed, run by Kyowa Kirin. The registered enrollment target is 114 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower). The trial reports 15 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02705105, a Phase 1 study of Cancer and Solid Tumor, has completed, sponsored by Kyowa Kirin.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 114 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of mogamulizumab and nivolumab in subjects with locally advanced or metastatic solid tumors.
Primary Outcome
The MTD was defined as one dose level below the dose level of the cohort where ≥ one-third of the subjects experienced a dose-limiting toxicity (DLT)
Conditions Studied
Interventions
- BIOLOGICAL Mogamulizumab + Nivolumab
Study Locations (15)
California
- - Greenbrae
- - Los Angeles
Arizona
- - Gilbert
Florida
- - Jacksonville
Georgia
- - Augusta
Illinois
- - Chicago
Maryland
- - Baltimore
Michigan
- - Kalamazoo
New Jersey
- - Piscataway
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2016-02 |
| Est. Completion | 2018-10-10 |
| Phase | Phase 1 |
What the finished NCT02705105 record still lists
NCT02705105 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (97% lower).
The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Mogamulizumab + Nivolumab is the first listed.
NCT02705105 lists 15 locations in 14 states (California, Arizona, Florida).
Frequently Asked Questions
What is clinical trial NCT02705105 about?
NCT02705105 is a clinical study titled "Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors". The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of mogamulizumab and nivolumab in subjects with locally advanced or metastatic solid tumors.
What is the current status of trial NCT02705105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2016-02. Estimated completion is 2018-10-10.
What conditions does trial NCT02705105 study?
This clinical trial studies the following conditions: Cancer, Solid Tumor, Hepatocellular Carcinoma, Carcinoma, HCC.
What interventions are being tested in trial NCT02705105?
The interventions under investigation include: Mogamulizumab + Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02705105?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02705105 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02705105's enrollment target sits among peer trials
114 297th of 615 higher than 317 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia